BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Joshi S, Joshi M, Degani MS. Tackling SARS-CoV-2: proposed targets and repurposed drugs. Future Med Chem 2020;12:1579-601. [PMID: 32564623 DOI: 10.4155/fmc-2020-0147] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 11.0] [Reference Citation Analysis]
Number Citing Articles
1 Uma Reddy B, Routhu NK, Kumar A. Multifaceted role of plant derived small molecule inhibitors on replication cycle of sars-cov-2. Microbial Pathogenesis 2022. [DOI: 10.1016/j.micpath.2022.105512] [Reference Citation Analysis]
2 Moghaddam A, Heller RA, Sun Q, Seelig J, Cherkezov A, Seibert L, Hackler J, Seemann P, Diegmann J, Pilz M, Bachmann M, Minich WB, Schomburg L. Selenium Deficiency Is Associated with Mortality Risk from COVID-19.Nutrients. 2020;12. [PMID: 32708526 DOI: 10.20944/preprints202007.0113.v1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Kamel NA, El Wakeel LM, Aboshanab KM. Exploring SARS-CoV-2 Spikes Glycoproteins for Designing Potential Antiviral Targets. Viral Immunol 2021. [PMID: 34018828 DOI: 10.1089/vim.2021.0023] [Reference Citation Analysis]
4 Naidu SAG, Tripathi YB, Shree P, Clemens RA, Naidu AS. Phytonutrient Inhibitors of SARS-CoV-2/NSP5-Encoded Main Protease (Mpro) Autocleavage Enzyme Critical for COVID-19 Pathogenesis. J Diet Suppl 2021;:1-28. [PMID: 34821532 DOI: 10.1080/19390211.2021.2006388] [Reference Citation Analysis]
5 Wall H. Welcome to volume 13 of Future Medicinal Chemistry. Future Med Chem 2021;13:1-3. [PMID: 33319591 DOI: 10.4155/fmc-2020-0338] [Reference Citation Analysis]
6 Dampalla CS, Zheng J, Perera KD, Wong LR, Meyerholz DK, Nguyen HN, Kashipathy MM, Battaile KP, Lovell S, Kim Y, Perlman S, Groutas WC, Chang KO. Postinfection treatment with a protease inhibitor increases survival of mice with a fatal SARS-CoV-2 infection. Proc Natl Acad Sci U S A 2021;118:e2101555118. [PMID: 34210738 DOI: 10.1073/pnas.2101555118] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
7 [DOI: 10.1101/2021.02.05.429937] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
8 Ravi S, Jadhav S, Vaidya A, Ghooi R. Repurposing drugs during the COVID-19 pandemic and beyond. Pharm Pat Anal 2021;10:9-12. [PMID: 33445955 DOI: 10.4155/ppa-2020-0031] [Reference Citation Analysis]
9 Hatmal MM, Alshaer W, Al-Hatamleh MAI, Hatmal M, Smadi O, Taha MO, Oweida AJ, Boer JC, Mohamud R, Plebanski M. Comprehensive Structural and Molecular Comparison of Spike Proteins of SARS-CoV-2, SARS-CoV and MERS-CoV, and Their Interactions with ACE2. Cells 2020;9:E2638. [PMID: 33302501 DOI: 10.3390/cells9122638] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 11.5] [Reference Citation Analysis]
10 Cavezzi A, Menicagli R, Troiani E, Corrao S. COVID-19, Cation Dysmetabolism, Sialic Acid, CD147, ACE2, Viroporins, Hepcidin and Ferroptosis: A Possible Unifying Hypothesis. F1000Res 2022;11:102. [DOI: 10.12688/f1000research.108667.1] [Reference Citation Analysis]
11 Ostrov DA, Bluhm AP, Li D, Khan JQ, Rohamare M, Rajamanickam K, K Bhanumathy K, Lew J, Falzarano D, Vizeacoumar FJ, Wilson JA, Mottinelli M, Kanumuri SRR, Sharma A, McCurdy CR, Norris MH. Highly Specific Sigma Receptor Ligands Exhibit Anti-Viral Properties in SARS-CoV-2 Infected Cells. Pathogens 2021;10:1514. [PMID: 34832669 DOI: 10.3390/pathogens10111514] [Reference Citation Analysis]
12 Deganutti G, Prischi F, Reynolds CA. Supervised molecular dynamics for exploring the druggability of the SARS-CoV-2 spike protein. J Comput Aided Mol Des 2021;35:195-207. [PMID: 33103220 DOI: 10.1007/s10822-020-00356-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 5.5] [Reference Citation Analysis]
13 Shahabadi N, Mahdavi M, Zendehcheshm S. Can polyoxometalates (POMs) prevent of coronavirus 2019-nCoV cell entry? Interaction of POMs with TMPRSS2 and spike receptor domain complexed with ACE2 (ACE2-RBD): Virtual screening approaches. Informatics in Medicine Unlocked 2022;29:100902. [DOI: 10.1016/j.imu.2022.100902] [Reference Citation Analysis]
14 Yuce M, Cicek E, Inan T, Dag AB, Kurkcuoglu O, Sungur FA. Repurposing of FDA-approved drugs against active site and potential allosteric drug-binding sites of COVID-19 main protease. Proteins 2021. [PMID: 34169568 DOI: 10.1002/prot.26164] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Yan S, Wu G. Potential 3-chymotrypsin-like cysteine protease cleavage sites in the coronavirus polyproteins pp1a and pp1ab and their possible relevance to COVID-19 vaccine and drug development. FASEB J 2021;35:e21573. [PMID: 33913206 DOI: 10.1096/fj.202100280RR] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Hartini Y, Saputra B, Wahono B, Auw Z, Indayani F, Adelya L, Namba G, Hariono M. Biflavonoid as potential 3-chymotrypsin-like protease (3CLpro) inhibitor of SARS-Coronavirus. Results Chem 2021;3:100087. [PMID: 33520632 DOI: 10.1016/j.rechem.2020.100087] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
17 Agamennone M, Nicoli A, Bayer S, Weber V, Borro L, Gupta S, Fantacuzzi M, Di Pizio A. Protein-protein interactions at a glance: Protocols for the visualization of biomolecular interactions. Methods Cell Biol 2021;166:271-307. [PMID: 34752337 DOI: 10.1016/bs.mcb.2021.06.012] [Reference Citation Analysis]
18 Thakur S, Mayank, Sarkar B, Ansari AJ, Khandelwal A, Arya A, Poduri R, Joshi G. Exploring the magic bullets to identify Achilles' heel in SARS-CoV-2: Delving deeper into the sea of possible therapeutic options in Covid-19 disease: An update. Food Chem Toxicol 2021;147:111887. [PMID: 33253764 DOI: 10.1016/j.fct.2020.111887] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
19 Farooq S, Ngaini Z. Natural and Synthetic Drugs as Potential Treatment for Coronavirus Disease 2019 (COVID-2019). Chemistry Africa 2021;4:1-13. [DOI: 10.1007/s42250-020-00203-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
20 Kumar V, Parate S, Yoon S, Lee G, Lee KW. Computational Simulations Identified Marine-Derived Natural Bioactive Compounds as Replication Inhibitors of SARS-CoV-2. Front Microbiol 2021;12:647295. [PMID: 33967984 DOI: 10.3389/fmicb.2021.647295] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
21 Khuntia BK, Sharma V, Qazi S, Das S, Sharma S, Raza K, Sharma G. Ayurvedic Medicinal Plants Against COVID-19: An In Silico Analysis. Natural Product Communications 2021;16:1934578X2110567. [DOI: 10.1177/1934578x211056753] [Reference Citation Analysis]
22 Banerjee S, Yadav S, Banerjee S, Fakayode SO, Parvathareddy J, Reichard W, Surendranathan S, Mahmud F, Whatcott R, Thammathong J, Meibohm B, Miller DD, Jonsson CB, Dubey KD. Drug Repurposing to Identify Nilotinib as a Potential SARS-CoV-2 Main Protease Inhibitor: Insights from a Computational and In Vitro Study. J Chem Inf Model 2021;61:5469-83. [PMID: 34666487 DOI: 10.1021/acs.jcim.1c00524] [Reference Citation Analysis]
23 Reznikov LR, Norris MH, Vashisht R, Bluhm AP, Li D, Liao YJ, Brown A, Butte AJ, Ostrov DA. Identification of antiviral antihistamines for COVID-19 repurposing. Biochem Biophys Res Commun 2021;538:173-9. [PMID: 33309272 DOI: 10.1016/j.bbrc.2020.11.095] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
24 Moghaddam A, Heller RA, Sun Q, Seelig J, Cherkezov A, Seibert L, Hackler J, Seemann P, Diegmann J, Pilz M, Bachmann M, Minich WB, Schomburg L. Selenium Deficiency Is Associated with Mortality Risk from COVID-19. Nutrients 2020;12:E2098. [PMID: 32708526 DOI: 10.3390/nu12072098] [Cited by in Crossref: 79] [Cited by in F6Publishing: 69] [Article Influence: 39.5] [Reference Citation Analysis]
25 Melinda YN, Widada J, Wahyuningsih TD, Febriansah R, Damayanti E, Mustofa M. Metabologenomics approach to the discovery of novel compounds from Streptomyces sp. GMR22 as anti-SARS-CoV-2 drugs. Heliyon 2021;7:e08308. [PMID: 34746476 DOI: 10.1016/j.heliyon.2021.e08308] [Reference Citation Analysis]
26 Kumari A, Rajput VS, Nagpal P, Kukrety H, Grover S, Grover A. Dual inhibition of SARS-CoV-2 spike and main protease through a repurposed drug, rutin. J Biomol Struct Dyn 2020;:1-13. [PMID: 33357073 DOI: 10.1080/07391102.2020.1864476] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
27 Rani J, Bhargav A, Khan FI, Ramachandran S, Lai D, Bajpai U. In silico prediction of natural compounds as potential multi-target inhibitors of structural proteins of SARS-CoV-2. J Biomol Struct Dyn 2021;:1-17. [PMID: 34486935 DOI: 10.1080/07391102.2021.1968497] [Reference Citation Analysis]
28 [DOI: 10.1101/2020.08.30.273979] [Cited by in Crossref: 10] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
29 Gunst JD, Staerke NB, Pahus MH, Kristensen LH, Bodilsen J, Lohse N, Dalgaard LS, Brønnum D, Fröbert O, Hønge B, Johansen IS, Monrad I, Erikstrup C, Rosendal R, Vilstrup E, Mariager T, Bove DG, Offersen R, Shakar S, Cajander S, Jørgensen NP, Sritharan SS, Breining P, Jespersen S, Mortensen KL, Jensen ML, Kolte L, Frattari GS, Larsen CS, Storgaard M, Nielsen LP, Tolstrup M, Sædder EA, Østergaard LJ, Ngo HTT, Jensen MH, Højen JF, Kjolby M, Søgaard OS. Efficacy of the TMPRSS2 inhibitor camostat mesilate in patients hospitalized with Covid-19-a double-blind randomized controlled trial. EClinicalMedicine 2021;35:100849. [PMID: 33903855 DOI: 10.1016/j.eclinm.2021.100849] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 11.0] [Reference Citation Analysis]
30 Cavezzi A, Menicagli R, Troiani E, Corrao S. COVID-19, Cation Dysmetabolism, Sialic Acid, CD147, ACE2, Viroporins, Hepcidin and Ferroptosis: A Possible Unifying Hypothesis. F1000Res 2022;11:102. [DOI: 10.12688/f1000research.108667.2] [Reference Citation Analysis]
31 Vlachakis D, Papakonstantinou E, Mitsis T, Pierouli K, Diakou I, Chrousos G, Bacopoulou F. Molecular mechanisms of the novel coronavirus SARS-CoV-2 and potential anti-COVID19 pharmacological targets since the outbreak of the pandemic. Food Chem Toxicol 2020;146:111805. [PMID: 33038452 DOI: 10.1016/j.fct.2020.111805] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
32 Muralidar S, Gopal G, Visaga Ambi S. Targeting the viral-entry facilitators of SARS-CoV-2 as a therapeutic strategy in COVID-19. J Med Virol 2021;93:5260-76. [PMID: 33851732 DOI: 10.1002/jmv.27019] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]